Due to the Omicron variety spreads, the Central Drugs Standard Control Organisation and Ministry of Health and Family Welfare have approved two new vaccinations and antiviral medication to protect individuals from Covid-19.
Molnupiravir, developed by Merck & Co. and Ridgeback Biotherapeutics LP, the first anti-viral Covid-19 pill, was approved by the Indian drug regulator on Tuesday.
In India, the medicine has been approved for the treatment of people with Covid-19 who “who have a high risk of progression of the disease”.
13 Indian drug manufacturers will produce the medication domestically, according to Union Health Minister Mansukh Mandaviya. The medicine will be manufactured by Dr Reddy Laboratories, Cipla, Natco Pharma, Optimus Pharma Pvt Ltd, Stride, and Hetero, among other prominent pharmaceutical companies.
Molnupiravir is an antiviral that inhibits SARS-CoV-2 replication by viral mutagenesis. The antiviral drug will now be manufactured in the country by 13 companies for restricted use under emergencies for the treatment of adult patients with COVID-19 and who have a high risk of progression of the disease,”
Health Minister Mandaviya said.
Usage Of Molnupiravir To Treat SARS-CoV-2
Molnupiravir (MK-4482, EIDD-2801) has been repurposed for a cause!
So the medicine was developed to treat influenza not covid. But the medicine “Molnupiravir (MK-4482, EIDD-2801)” can prevent the SARS-CoV-2 virus from replicating further by introducing errors into its genetic code.
The drug is given orally in four 200 milligramme capsules every 12 hours for five days, totalling 40 capsules. Molnupiravir should not be used for more than five days in a row, according to the USFDA.
Molnupiravir was cleared in “certain adults” in the United States on December 23.
“It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because the benefit of treatment has not been observed in people when treatment started after hospitalization due to COVID-19,”
The USFDA said.
Molnupiravir: Restrictions And Conditions
- The medicine sold by retail under the supervision of medical specialists.
- The recommended dose is 800mg twice daily for five days.
- Molnupiravir should not be used for more than five days in a row, according to the USFDA.
- Molnupiravir is not approved for use in patients younger than 18 years old because it can disrupt bone and cartilage formation.
“Considering the emergency and unmet medical need in Covid-19, the SEC on December 27 recommended for grant of permission to manufacture and market the Molnupiravir 200mg capsule for restricted use under an emergency in the country for treatment of adult patients with COVID-19,”
The statement said.
Comments are closed, but trackbacks and pingbacks are open.